A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Ceramides-lipid molecules in cells that affect many physiological functions including cell differentiation, migration, and ...